They suggested that IST holds potential as an off-label cancer treatment, promoting an anti-tumor response through the production of pro-inflammatory cytokines and inhibition of the AKT/mTOR tumor growth pathway [14,15,16,17]. This evidence concerns the gene AKT1 and neoplasm.